Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

MRD GATE RCC: observation instead of adjuvant pembrolizumab when MRD is undetectable

Phase 2 study in which patients with resected clear-cell renal cell carcinoma who would otherwise receive adjuvant pembrolizumab are observed if molecular residual disease is not detected, and continue pembrolizumab if it is.

University of Alabama at Birmingham